Coegin Pharma

Pre-clinical

Stockholm, SwedenFounded 2017coeginpharma.com

Coegin Pharma is a Swedish biotech firm that has transitioned from traditional drug development to focus exclusively on premium cosmetic peptides for hair and skin. Its core strategy leverages the global longevity megatrend, commercializing its patented Follicopeptide® for hair density and developing NPP-4 for skin toning. The company's innovations are built on collaborations with leading universities and are driven by a management team with deep expertise in biotechnology and commercialization.

Founded

2017

Focus

RNA & Gene TherapySmall Molecules

AI Company Overview

Technology Platform

Peptide-based biotechnology platform for developing cosmetic innovations targeting hair follicle health and skin pigmentation pathways, supported by academic research collaborations.

Funding History

Total raised: $2.5M

Seed$2.5MUndisclosedJun 15, 2021

Opportunities

The global longevity megatrend creates a massive, growing market for scientifically backed cosmetic products.

Success with Follicopeptide® can establish the brand and fund pipeline expansion.

The peptide technology platform has potential for additional applications in cosmetic dermatology beyond the two current lead programs.

Risk Factors

Intense competition from large cosmetic corporations and other cosmeceutical startups.

Commercialization risk for Follicopeptide® and development/delay risk for NPP-4.

As a private company, financial stability depends on product sales or securing additional funding, creating inherent financial risk.

Competitive Landscape

Competes with major cosmetic companies (L'Oréal, Estée Lauder) and specialty cosmeceutical brands in the hair growth and skin care markets. Differentiation is based on its biotech heritage, focus on peptide innovation, and academic collaborations, aiming to offer superior scientifically-backed efficacy.